GlassScriptPhysician profile
Michael Thomas Goldfarb
NPI 1467422923
$3,089.26
in general payments reported to CMS, 2019-2025
18 companies · $1,171 in 2025
The $1,171 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,254 · 2021: $245 · 2022: $39.65 · 2023: $83.57 · 2024: $296 · 2025: $1,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $792 · Travel and Lodging: $596 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.48 |
| Travel and Lodging | $596.03 |
| Education | $161.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,254.16 | 2019 | |
| Astrazeneca Uk Limited | $851.03 | 2025 | Saphnelo |
| Genzyme Corporation | $245.00 | 2021 | |
| Dermavant Sciences, INC. | $230.38 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $145.98 | 2024-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.30 | 2025 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $63.05 | 2022-2024 | Sotyktu |
| Abbvie INC. | $48.69 | 2025 | |
| Botanix Sb INC | $39.04 | 2025 | Sofdra |
| Organon LLC | $23.92 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.84 | 2025 | Jublia, Cabtreo, Siliq |
| Pfizer INC. | $23.63 | 2025 | |
| Lilly USA, LLC | $21.78 | 2025 | Ebglyss, Taltz |
| Regeneron Healthcare Solutions, INC. | $15.96 | 2024 | Libtayo |
| Leo Pharma INC. | $14.85 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $14.65 | 2024 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Goldfarb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.